Fosun Pharma’s US$1.3 billion bid to acquire Gland Pharma could be in jeopardy amid the escalating bilateral dispute between China and India. Photo: Imaginechina
Will Fosun’s deal go ahead amid the Sino-Indian spat?
Fosun Pharma claims that it is still waiting for approval from Indian authorities, despite reports that the deal is expected to be rejected
Fosun Pharma’s US$1.3 billion bid to acquire Gland Pharma could be in jeopardy amid the escalating bilateral dispute between China and India. Photo: Imaginechina
